| Alder Biopharmaceuticals is a clinical-stage biopharmaceutical company that discovers, develops and seeks to commercialize therapeutic antibodies with the potential to transform the treatment paradigm in migraine. Co. is focusing on eptinezumab (ALD403). Eptinezumab is a humanized immunoglobulin G1 monoclonal antibody for calcitonin gene-related peptide ligand, a small protein and a target to drive migraine initiation, maintenance and chronification. Co.'s product candidate pipeline also includes ALD1910, a neutralizing monoclonal antibody with reactivity to that targets pituitary adenylate cyclase-activating polypeptide-38. We show 24 historical shares outstanding datapoints in our coverage of ALDR's shares outstanding history.|
Understanding the changing numbers of ALDR shares outstanding — and
comprehending the concept of differing number of shares outstanding in general comparing companies like ALDR versus peers —
is critical for investors. Many "beginner" or "novice" investors will look at one stock trading at a price of $10 per share and another trading at
a price of $20 per share and think the latter company is worth twice as much. Of course, that is a completely meaningless comparison without also knowing how many shares outstanding there are for each of the two companies.
Furthermore, via issuance of new shares over time, or the repurchase of existing shares, the number of shares outstanding can fluctuate over the course of history.
With this page we aim to empower investors researching ALDR by allowing them to research ALDR shares outstanding history
as well as any other stock in our coverage universe.